# Cilostazol and Aspirin in Stroke and TIA

Study · id `cardio:ct-nct06522113` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06522113](<https://clinicaltrials.gov/study/NCT06522113>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06522113

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 378 participants.

## Technical summary

Registry record NCT06522113. Randomized; no masking; primary purpose treatment. Start 2019-07-18 (actual); primary completion 2022-10-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 378 participants (enrolled count; ClinicalTrials.gov record NCT06522113, source copy `cardio:ctgov-nct06522113-2024-08-06`, retrieved 2026-10-26)
- Started: 2019-07-18 (actual) (ClinicalTrials.gov record NCT06522113, source copy `cardio:ctgov-nct06522113-2024-08-06`, retrieved 2026-10-26)
- Primary completion: 2022-10-17 (actual) (ClinicalTrials.gov record NCT06522113, source copy `cardio:ctgov-nct06522113-2024-08-06`, retrieved 2026-10-26)
- Completion: 2022-10-17 (actual) (ClinicalTrials.gov record NCT06522113, source copy `cardio:ctgov-nct06522113-2024-08-06`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06522113, source copy `cardio:ctgov-nct06522113-2024-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06522113-2024-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cilostazol and Aspirin in Stroke and TIA
- Condition: Ischemic Stroke
- Condition: TIA
- Intervention (Drug): Cilostazol
- Intervention (Drug): Clopidogrel
- Lead sponsor: Incheon St.Mary's Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: Incheon St.Mary's Hospital (`cardio:org-incheon-st-mary-s-hospital`)

## Provenance

Content hash: b32a6cef74177365ae85df06a41201fe5f2a3898c7978a5361b27156f385519b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
